VIA
HAE icon

Vident Investment Advisory’s Haemonetics HAE Stock Holding History

Vident Investment Advisory’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-27,638
Closed -$893K – 566
2015
Q3 		$893K Buy
27,638
+7,027
+34% +$264K 0.12% 229
2015
Q2 		$852K Buy
20,611
+972
+5% +$41K 0.11% 230
2015
Q1 		$882K Buy
+19,639
New +$821K 0.18% 154

Other funds holding HAE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Vident Investment Advisory's HAE Position: Q4 2015 in Review

Vident Investment Advisory sold out of Haemonetics (HAE) in Q4 2015, closing a stake of 27,638 shares — an estimated $893K sold.

Vident Investment Advisory first reported a position in HAE in Q1 2015 and held it in 3 quarters. The position peaked at $893K in Q3 2015. 164 funds tracked by Wall St. Rank hold HAE as of Q4 2015.

  • Vident Investment Advisory reported no remaining Haemonetics position as of Q4 2015 after selling out during the quarter.
  • Vident Investment Advisory sold 27,638 Haemonetics shares in Q4 2015, an estimated $893K.
  • Vident Investment Advisory first reported a position in Haemonetics in Q1 2015 and held it in 3 quarters.
  • Vident Investment Advisory's Haemonetics position peaked at $893K in Q3 2015.
  • 164 funds tracked by Wall St. Rank held Haemonetics as of Q4 2015.

Based on Vident Investment Advisory's 13F filing for Q4 2015, filed 17 Feb 2016.